CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Zepbound joins the GLP-1 ranks for weight loss with Wegovy and Saxenda. Tirzepatide is the main ingredient in Zepbound, approved label for weight management, and Mounjaro, the brand name approved ...